ArticleFrontiers in plant science2022
Protein Engineering of a Germacrene A Synthase From
Article in Frontiers in plant science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Developing a highly efficient whole-cell biotransformation of 3,4-dihydroxyacetophenone into Apocynin by engineered Escherichia coli expressing caffeic acid O-methyltransferase.World journal of microbiology & biotechnology · 2025Article
- Characterization and functional reconstruction of a highly productive germacrene A synthase from Liriodendron chinense.Plant biotechnology journal · 2025Article
- Exploration and mutagenesis of the germacrene A synthase fromSynthetic and systems biotechnology · 2025Article
- Microbial production of 5-Applied and environmental microbiology · 2024Article
- Recent advances in lycopene and germacrene a biosynthesis and their role as antineoplastic drugs.World journal of microbiology & biotechnology · 2024Review
- An Investigation of the JAZ Family and the CwMYC2-like Protein to Reveal Their Regulation Roles in the MeJA-Induced Biosynthesis of β-Elemene inInternational journal of molecular sciences · 2023Article
- Development of a Pichia pastoris cell factory for efficient production of germacrene A: a precursor of β-elemene.Bioresources and bioprocessing · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Germacrene A (GA) is a key intermediate for the synthesis of medicinal active compounds, especially for β-elemene, which is a broad-spectrum anticancer drug. The production of sufficient GA in the microbial platform is vital for the precursors supply of active compounds. In this study,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.